The genetics of phaeochromocytoma: Using clinical features to guide genetic testing

European Journal of Endocrinology

Volumn 166, Issue 2, 2012, Pages 151-158

  Jafri, Mariam ^a,b   Maher, Eamonn R ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMODECTOMA; CLINICAL FEATURE; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOHISTOCHEMISTRY; MAX GENE; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; NEUROFIBROMATOSIS 1 GENE; PENETRANCE; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RET GENE; REVIEW; SUCCINATE DEHYDROGENASE COMPLEX GENE; TMEM127 GENE; TUMOR GENE; VON HIPPEL LINDAU GENE;

ADRENAL GLAND NEOPLASMS; GENES, NEUROFIBROMATOSIS 1; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRACTICE GUIDELINES AS TOPIC; PROTO-ONCOGENE PROTEINS C-RET; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84856118165     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0497     Document Type: Review

References (60)

1. Gimenez-Roqueplo AP, Lehnert H, Mannelli M, Neumann H, Opocher G, Maher ER & Plouin PF & European Network for the Study of Adrenal Tumours (ENS@T) Phaeochromocytoma Working Group. Phaeochromocytoma, new genes and screening strategies. Clinical Endocrinology 2006 65 699-705. (doi:10.1111/j.1365-2265.2006.02714.x)
2. Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT & Ferguson-Smith MA. Clinical features and natural history of von Hippel-Lindau disease. Quarterly Journal of Medicine 1990 77 1151-1163.
3. Ong KR,Woodward ER, Killick P, Lim C, Macdonald F & Maher ER. Genotype-phenotype correlations in von Hippel-Lindau disease. Human Mutation 2007 28 143-149. (doi:10.1002/humu.20385)
4. Maher ER, Neumann HP & Richard S. von Hippel-Lindau disease: a clinical and scientific review. European Journal of Human Genetics 2011 19 617-623. (doi:10.1038/ejhg.2010.175)
5. Boedeker CC, Erlic Z, Richard S, Kontny U, Gimenez-Roqueplo AP, Cascon A, Robledo M, de Campos JM, van Nederveen FH, de Krijger RR, Burnichon N, Gaal J, Walter MA, Reschke K, Wiech T, Weber J, Rückauer K, Plouin PF, Darrouzet V, Giraud S, Eng C & Neumann HP. Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. Journal of Clinical Endocrinology and Metabolism 2009 94 1938-1944. (doi:10.1210/jc.2009- 0354)
6. Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, Lerman MI, Zbar B, Affara NA, Ferguson-Smith MA & Maher ER. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Human Molecular Genetics 1994 3 1303-1308. (doi:10.1093/hmg/3.8.1303)
7. Woodward ER, Eng C, McMahon R, Voutilainen R, Affara NA, Ponder BA & Maher ER. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. Human Molecular Genetics 1997 6 1051-1056. (doi:10.1093/hmg/6.7.1051)
8. Moline J & Eng C. Multiple endocrine neoplasia type 2: an overview. Genetics in Medicine 2011 13 755-764.
9. Neumann HP, Vortmeyer A, Schmidt D, Werner M, Erlic Z, Cascon A, Bausch B, Januszewicz A & Eng C. Evidence of MEN-2 in the original description of classic pheochromocytoma. New England Journal of Medicine 2007 357 1311-1315. (doi:10.1056/NEJMoa071407)
10. Eng C, Clayton D, Schuffenecker I, Lenoir G, Coke G, Gagel RF, van Arnstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, NollWW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN & Mulligan LM. The relationship between specific RET protooncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. Journal of the American Medical Association 1996 276 1575-1579.
11. Gujral TS, Singh VK, Jia Z & Mulligan LM. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B. Cancer Research 2006 66 10741-10749. (doi:10.1158/0008-5472.CAN-06-3329)
12. Eng C. Common alleles of predisposition in endocrine neoplasia. Current Opinion in Genetics & Development 2010 20 251-256. (doi:10.1016/j.gde.2010. 02.004)
13. Neumann HP, Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier- Woelfle M, Peçzkowska M, Szmigielski C & Eng C. Germ-line mutations in nonsyndromic pheochromocytoma. New England Journal of Medicine 2002 346 1459-1466. (doi:10.1056/NEJMoa020152)
14. Opocher G & Schiavi F. Genetics of phaeochromocytomas and paragangliomas. Best Practice & Research. Clinical Endocrinology & Metabolism 2006 6 943-956.
15. Larizza L, Gervasini C, Natacci F & Riva P. Developmental abnormalities and cancer predisposition in neurofibromatosis type 1. Current Molecular Medicine 2009 9 634-653. (doi:10.2174/156652409788488801)
16. Bausch B, Koschker AC, Fassnacht M, Stoevesandt J, Hoffmann MM, Eng C, Allolio B & Neumann HP. Comprehensive mutation scanning of NF1 in apparently sporadic cases of pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 2006 91 3478-3481. (doi:10.1210/jc.2006-0780)
17. Jett K & Friedman JM. Clinical and genetic aspects of neurofibromatosis 1. Genetics in Medicine 2010 12 1-11. (doi:10.1097/GIM. 0b013e3181bf15e3)
18. Lu-Emerson C & Plotkin SR. The neurofibromatoses. Part 1: NF1. Reviews in Neurological Diseases 2009 6 E47-E53.
19. Bausch B, Borozdin W, Mautner VF, Hoffmann MM, Boehm D, Robledo M, Cascon A, Harenberg T, Schiavi F, Pawlu C, Peczkowska M, Letizia C, Calvieri S, Arnaldi G, Klingenberg- Noftz RD, Reisch N, Fassina A, Brunaud L, Walter MA, Mannelli M, MacGregor G, Palazzo FF, Barontini M, Walz MK, Kremens B, Brabant G, Pfäffle R, Koschker AC, Lohoefner F, Mohaupt M, Gimm O, Jarzab B, McWhinney SR, Opocher G, Januszewicz A, Kohlhase J, Eng C & Neumann HP & European- American Phaeochromocytoma Registry Study Group. Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. Journal of Clinical Endocrinology and Metabolism 2007 92 2784-2792. (doi:10.1210/jc.2006-2833)
20. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN, Richard CW III, Cornelisse CJ, Devilee P & Devlin B. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000 287 848-851. (doi:10.1126/science.287.5454.848)
21. Astuti D, Douglas F, Lennard TW, Aligianis IA, Woodward ER, Evans DG, Eng C, Latif F & Maher ER. Germline SDHD mutation in familial phaeochromocytoma. Lancet 2001a 357 1181-1182. (doi:10.1016/S0140-6736(00)04378- 6)
22. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A & Eng C & European-American Paraganglioma Study Group. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. Journal of the American Medical Association 2004 292 943-951. (doi:10.1001/jama.292.8.943)
23. Ricketts CJ, Forman JR, Rattenberry E, Bradshaw N, Lalloo F, Izatt L, Cole TR, Armstrong R, Kumar VK, Morrison PJ, Atkinson AB, Douglas F, Ball SG, Cook J, Srirangalingam U, Killick P, Kirby G, Aylwin S,Woodward ER, Evans DG, Hodgson SV, Murday V, Chew SL, Connell JM, Blundell TL, Macdonald F & Maher ER. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Human Mutation 2010 31 41-51. (doi:10.1002/humu.21136)
24. Pigny P, Vincent A, Cardot Bauters C, Bertrand M, de Montpreville VT, Crepin M, Pardet N & Caron P. Paraganglioma after maternal transmission of succinate dehydrogenase gene mutation. Journal of Clinical Endocrinology and Metabolism 2008 93 1609-1615. (doi:10.1210/jc.2007-1989)
25. Neumann HP & Erlic Z. Maternal transmission of symptomatic disease with SDHD mutation: fact or fiction. Journal of Clinical Endocrinology and Metabolism 2008 93 1573-1575. (doi:10.1210/jc.2008-0569)
26. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Skoldberg F, Husebye ES, Eng C & Maher ER. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. American Journal of Human Genetics 2001b 69 49-54. (doi:10.1086/321282)
27. Ricketts C, Woodward ER, Killick P, Morris MR, Astuti D, Latif F & Maher ER. Germline SDHB mutations and familial renal cell carcinoma. Journal of the National Cancer Institute 2008 100 1260-1262. (doi:10.1093/jnci/djn254)
28. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau Van Kien P, Corvol P, Plouin PF & Jeunemaitre X & COMETE Network. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Research 2003 63 5615-5621.
29. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A, Niccoli-Sire P, Richard S, Rohmer V, Sadoul JL, Strompf L, Schlumberger M, Bertagna X, Plouin PF, Jeunemaitre X & Gimenez-Roqueplo AP. Genetic testing in pheochromocytoma or functional paraganglioma. Journal of Clinical Oncology 2005 23 8812-8818. (doi:10.1200/JCO.2005.03.1484)
30. Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM & Pacak K. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. Journal of Clinical Endocrinology and Metabolism 2006 91 4505-4509. (doi:10.1210/jc.2006-0423)
31. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, Bertagna X, Schlumberger M, Jeunemaitre X, Gimenez- Roqueplo AP & Plouin PF. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. Journal of Clinical Endocrinology and Metabolism 2007 92 3822-3828. (doi:10.1210/jc.2007-0709)
32. Schiavi F, Milne RL, Anda E, Blay P, Castellano M, Opocher G, Robledo M & Cascón A. Are we overestimating the penetrance of mutations in SDHB? Human Mutation 2010 31 761-762. (doi:10.1002/humu.21269)
33. Pasini B, McWhinney SR, Bei T, Matyakhina L, Stergiopoulos S, Muchow M, Boikos SA, Ferrando B, Pacak K, Assie G, Baudin E, Chompret A, Ellison JW, Briere JJ, Rustin P, Gimenez-Roqueplo AP, Eng C, Carney JA & Stratakis CA. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. European Journal of Human Genetics 2008 16 79-88. (doi:10.1038/sj.ejhg.5201904)
34. Janeway KA, Kim SY, Lodish M, Nosé V, Rustin P, Gaal J, Dahia PL, Liegl B, Ball ER, Raygada M, Lai AH, Kelly L, Hornick JL, O'Sullivan M, de Krijger RR, Dinjens WN, Demetri GD, Antonescu CR, Fletcher JA, Helman L & Stratakis CA. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. PNAS 2011 108 314-318. (doi:10.1073/pnas.1009199108)
35. Mannelli J, Ercolino T, Giache V, Simi L, Cirami C & Paranti G. Genetic screening for phaeochromocytoma: should SDHC gene analysis be included? Journal of Medical Genetics 2007 44 586-587. (doi:10.1136/jmg.2007.051045)
36. Peczkowska M, Cascon A, Prejbisz A, Kubaszek A, Cwiskla BJ, Furmanek M, Erlic Z & Eng C. Extra-adrenal and adrenal phaeochromocytomas associated with a germline SDHC mutation. Nature Clinical Practice. Endocrinology & Metabolism 2008 4 111-115. (doi:10.1038/ncpendmet0726)
37. Schiavi F, Boedeker CC, Bausch B, Peçzkowska M, Gomez CF, Strassburg T, Pawlu C, Buchta M, Salzmann M, Hoffmann MM, Berlis A, Brink I, Cybulla M, Muresan M, Walter MA, Forrer F, Välimäki M, Kawecki A, Szutkowski Z, Schipper J, Walz MK, Pigny P, Bauters C, Willet-Brozick JE, Baysal BE, Januszewicz A, Eng C, Opocher G & Neumann HP & European-American Paraganglioma Study Group. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. Journal of the American Medical Association 2005 294 2057-2063. (doi:10.1001/jama.294.16.2057)
38. Timmers HJ, Gimenez-Roqueplo AP, Mannelli M & Pacak K. Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocrine-Related Cancer 2009 16 391-400. (doi:10.1677/ERC-08-0284)
39. Burnichon N, Rohmer V, Amar L, Herman P, Leboulleux S, Darrouzet V, Niccoli P, Gaillard D, Chabrier G, Chabolle F, Coupier I, Thieblot P, Lecomte P, Bertherat J, Wion-Barbot N, Murat A, Venisse A, Plouin PF, Jeunemaitre X & Gimenez- Roqueplo AP & PGLNET network. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. Journal of Clinical Endocrinology and Metabolism 2009 94 2817-2827. (doi:10.1210/jc. 2008-2504)
40. Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgeois M, Viegas-Pequignot E, Munnich A & Rotig A. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nature Genetics 1995 11 144-149. (doi:10.1038/ng1095-144)
41. Burnichon N, Brière JJ, Libé R, Vescovo L, Rivière J, Tissier F, Jouanno E, Jeunemaitre X, Bénit P, Tzagoloff A, Rustin P, Bertherat J, Favier J & Gimenez-Roqueplo AP. SDHA is a tumor suppressor gene causing paraganglioma. Human Molecular Genetics 2010 19 3011-3020. (doi:10.1093/hmg/ddq206)
42. Korpershoek E, Favier J, Gaal J, Burnichon N, van Gessel B, Oudijk L, Badoual C, Gadessaud N, Venisse A, Bayley JP, van Dooren MF, de HerderWW, Tissier F, Plouin PF, van Nederveen FH, Dinjens WN, Gimenez-Roqueplo AP & de Krijger RR. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. Journal of Clinical Endocrinology and Metabolism 2011 96 E1472-E1476. (doi:10.1210/jc.2011-1043)
43. Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, Lechleiter JD, Sass M, Aronin N, Schiavi F, Boaretto F, Opocher G, Toledo RA, Toledo SP, Stiles C, Aguiar RC & Dahia PL. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nature Genetics 2010 42 229-233. (doi:10.1038/ng.533)
44. Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Pérez L, King EE, Toledo RA, Ercolino T, Rapizzi E, Ricketts CJ, Mori L, Giacchè M, Mendola A, Taschin E, Boaretto F, Loli P, Iacobone M, Rossi GP, Biondi B, Lima-Junior JV, Kater CE, Bex M, Vikkula M, Grossman AB, Gruber SB, Barontini M, Persu A, Castellano M, Toledo SP, Maher ER, Mannelli M, Opocher G, Robledo M & Dahia PL. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. Journal of the American Medical Association 2010 304 2611-2619. (doi:10.1001/jama.2010.1830)
45. Neumann HP, Sullivan M, Winter A, Malinoc A, Hoffmann MM, Boedeker CC, Bertz H, Walz MK, Moeller LC, Schmid KW & Eng C. Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. Journal of Clinical Endocrinology and Metabolism 2011 96 E1279-E1282. (doi:10.1210/jc.2011-0114)
46. Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, Landa I, Leandro- García LJ, Letón R, Honrado E, Ramos-Medina R, Caronia D, Pita G, Gómez-Graña A, de Cubas AA, Inglada-Pérez L, Maliszewska A, Taschin E, Bobisse S, Pica G, Loli P, Hernández- Lavado R, Díaz JA, Gómez-Morales M, González-Neira A, Roncador G, Rodríguez-Antona C, Benítez J, Mannelli M, Opocher G, Robledo M & Cascón A. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genetics 2011 43 663-667. (doi:10.1038/ng.861)
47. Munirajan AK, Ando K, Mukai A, Takahashi M, Suenaga Y, Ohira M, Koda T, Hirota T, Ozaki T & Nakagawara A. KIF1Bbeta functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death. Journal of Biological Chemistry 2008 283 24426-24434. (doi:10.1074/jbc.M802316200)
48. Ladroue C, Carcenac R, Leporrier M, Gad S, Le Helloe C, Galateau- Salle F, Feunteun J, Pouysségur J, Richard S & Gardie B. PHD2 mutation and congenital erythrocytosis with paraganglioma. New England Journal of Medicine 2008 359 2685-2692. (doi:10.1056/NEJMoa0806277)
49. Yeh IT, Lenci RE, Qin Y, Buddavarapu K, Ligon AH, Leteurtre E, Do Cao C, Cardot-Bauters C, Pigny P & Dahia PL. A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors. Human Genetics 2008 124 279-285. (doi:10.1007/s00439-008-0553-1)
50. Astuti D, Ricketts CJ, Chowdhury R, McDonough MA, Gentle D, Kirby G, Schlisio S, Kenchappa RS, Carter BD, Kaelin WG Jr, Ratcliffe PJ, Schofield CJ, Latif F & Maher ER. Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. Endocrine-Related Cancer 2010 18 73-83. (doi:10.1677/ERC-10- 0113)
51. Hao HX, Khalimonchuk O, Schraders M, Dephoure N, Bayley JP, Kunst H, Devilee P, Cremers CW, Schiffman JD, Bentz BG, Gygi SP, Winge DR, Kremer H & Rutter J. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 2009 325 1139-1142. (doi:10.1126/science. 1175689)
52. Bayley JP, Kunst HP, Cascon A, Sampietro ML, Gaal J, Korpershoek E, Hinojar-Gutierrez A, Timmers HJ, Hoefsloot LH, Hermsen MA, Suárez C, Hussain AK, Vriends AH, Hes FJ, Jansen JC, Tops CM, Corssmit EP, de Knijff P, Lenders JW, Cremers CW, Devilee P, Dinjens WN, de Krijger RR & Robledo M. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncology 2010 11 366-372. (doi:10.1016/S1470-2045(10)70007-3)
53. Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JF, Tischler AS, Hodin R, Heitritter S, Moore F, Dluhy R, Sosa JA, Ocal IT, Benn DE, Marsh DJ, Robinson BG, Schneider K, Garber J, Arum SM, Korbonits M, Grossman A, Pigny P, Toledo SP, Nosé V, Li C & Stiles CD. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genetics 2005 1 72-80. (doi:10.1371/journal.pgen. 0010008)
54. Pollard PJ, El-Bahrawy M, Poulsom R, Elia G, Killick P, Kelly G, Hunt T, Jeffery R, Seedhar P, Barwell J, Latif F, Gleeson MJ, Hodgson SV, Stamp GW, Tomlinson IP & Maher ER. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. Journal of Clinical Endocrinology and Metabolism 2006 91 4593-4598. (doi:10.1210/jc.2006-0920)
55. Burnichon N, Vescovo L, Amar L, Libé R, de Reynies A, Venisse A, Jouanno E, Laurendeau I, Parfait B, Bertherat J, Plouin PF, Jeunemaitre X, Favier J & Gimenez-Roqueplo AP. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Human Molecular Genetics 2011.
56. Huynhh TT, Pack K, Wang DL, Linehan WM, Goldsterin DS, Eikahloun AG, Munson PJ & Eisenhoser G. Transcriptional regulation of phenylethanolamine n-methyltransferases in phaeochromocytoma from patients with von Hippel-Lindau syndrome and MEN type 2. Annals of the New York Academy of Sciences 2006 1073 241-252. (doi:10.1196/annals.1353.026)
57. Erlic Z, Rybicki L, Peczkowska M, Golcher H, Kann PH, Brauckhoff M, Müssig K, Muresan M, Schäffler A, Reisch N, Schott M, Fassnacht M, Opocher G, Klose S, Fottner C, Forrer F, Plöckinger U, Petersenn S, Zabolotny D, Kollukch O, Yaremchuk S, Januszewicz A,Walz MK, Eng C & Neumann HP. Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clinical Cancer Research 2009 15 6378-6385. (doi:10.1158/1078-0432.CCR-09-1237)
58. van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, Sleddens HF, Derkx P, Rivière J, Dannenberg H, Petri BJ, Komminoth P, Pacak K, Hop WC, Pollard PJ, Mannelli M, Bayley JP, Perren A, Niemann S, Verhofstad AA, de Bruïne AP, Maher ER, Tissier F, Méatchi T, Badoual C, Bertherat J, Amar L, Alataki D, Van Marck E, Ferrau F, François J, de Herder WW, Peeters MP, van Linge A, Lenders JW, Gimenez-Roqueplo AP, de Krijger RR & Dinjens WN. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: retrospective and prospective analysis. Lancet Oncology 2009 8 764-771. (doi:10.1016/S1470-2045(09)70164-0)
59. López-Jiménez E, Gómez-López G, Leandro-García LJ, Muñoz I, Schiavi F, Montero-Conde C, de Cubas AA, Ramires R, Landa I, Leskelä S, Maliszewska A, Inglada-Pérez L, de la Vega L, Rodríguez-Antona C, Letón R, Bernal C, de Campos JM, Diez- Tascón C, Fraga MF, Boullosa C, Pisano DG, Opocher G, Robledo M & Cascón A. Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Molecular Endocrinology 2010 24 2382-2391. (doi:10.1210/me.2010-0256)
60. Hoischen A, Gilissen C, Arts P, Wieskamp N, van der Vliet W, Vermeer S, Steehouwer M, de Vries P, Meijer R, Seiqueros J, Knoers NV, Buckley MF, Scheffer H & Veltman JA. Massively parallel sequencing of ataxia genes after array-based enrichment. Human Mutation 2010 31 494-499. (doi:10.1002/humu.21221)